Remission From Stage D Heart Failure
Purpose
The purpose of this study is to determine the proportion of subjects who have sufficient improvement in ventricular function after undergoing a standardized Left Ventricular Assist Device (LVAD) plus pharmacologic recovery treatment and testing protocol to allow removal of the LVAD within 18 months.
Conditions
- Heart Failure NYHA Class III
- Heart Failure NYHA Class IV
Eligibility
- Eligible Ages
- Between 18 Years and 59 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Subject age between 18 - 59 years, inclusive 2. Subject indicated for DT or BTT 3. Subject with severe clinical heart failure resistant to intensive medical therapy and requiring LVAD implantation 4. Subject with LVEF < 25% and cardiomegaly at the time of LVAD implantation as documented by radionuclide or contrast ventriculography or by echocardiography 5. Subject with non-ischemic etiology (confirmed by angiography either within 2 years of implantation or prior to explantation) 6. Subject have undergone HM II implantation within prior 4 weeks or planned for a HM II implant 7. Subject has a history of HF < 5 years.
Exclusion Criteria
- Subject has evidence of active acute myocarditis confirmed by histology 2. Subject has a history of previous CVA resulting in significant fixed motor deficit limiting ability to perform exercise testing 3. Subject has been implanted with a mechanical aortic and/or mitral valve(s) 4. Subject had an aortic valve closure 5. Subject diagnosed with a hypertrophic obstructive cardiomyopathy or sarcoidosis 6. Subject with LVEDD below normal confirmed by surface echocardiogram (restrictive cardiomyopathy) 7. Subject has irreversible multi-organ failure 8. Pregnant or lactating women or unwilling to utilize two reliable methods of birth control for women of childbearing age 9. Subject is diagnosed with a psychiatric disease, irreversible cognitive dysfunction or poor psychosocial issues that is likely to impair compliance with the study protocol 10. Subject with any condition, other than heart failure, that could limit survival to less than 2 years 11. Subject has a history of cardiac or other organ transplant 12. Subject is contraindicated to anticoagulation antiplatelet therapy 13. Subject requires acute or chronic renal replacement therapy (e.g. chronic dialysis) within 3 months prior to enrollment 14. Subject participating in any other clinical investigations involving another Mechanical Circulatory Support (MCS) device or heart failure related drug, or investigations which are likely to confound study results or affect study outcome.
Study Design
- Phase
- Phase 4
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental HeartMate II plus Pharmacological Treat |
The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta. The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily. |
|
Recruiting Locations
More Details
- Status
- Unknown status
- Sponsor
- University of Louisville
Detailed Description
The encouraging results from the LVAD based recovery series suggest that the significant hemodynamic unloading provided by the Mechanical Circulatory Support (MCS) in conjunction with aggressive pharmacological treatment may induce a profound reverse structural remodeling and in turn result in a curative alternative to a specific patient population with severe heart failure. The active identification and characterization of the patients with a high potential for full cardiac function recovery is of paramount importance. The development of a standard and simplified recovery protocol would ultimately lead to a larger bridge to recovery patient population. The primary objective of this study is to determine the proportion of subjects who have sufficient improvement in ventricular function (remission from heart failure) after undergoing a standardized LVAD plus pharmacologic recovery treatment and testing protocol to allow removal of the LVAD within 18 months. The secondary objectives of this study are twofold, first to determine the durability of sustained remission from HF following LVAD explantation at 12 months and up to 3 years and second to determine the predictors of recovery.